LSE - Delayed Quote GBp

MaxCyte, Inc. (MXCT.L)

316.00 +3.00 (+0.96%)
As of 8:06 AM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
NameTitlePayExercisedYear Born
Mr. Maher Masoud President, CEO, Secretary & Director 491.51k -- 1976
Mr. Douglas Arthur Doerfler Founder 963.35k -- 1956
Mr. Douglas J. Swirsky CFA, CPA Chief Financial Officer -- -- 1969
Mr. Jay Gelfman Senior Vice President of Operations -- -- --
Mr. Ronald Evan Holtz CPA, Ph.D. Executive Vice President of Administration 521.48k -- 1958
Mr. Sean Menarguez Director of Investor Relations -- -- --
Mr. David Sandoval Senior Vice President & General Counsel -- -- --
Mr. Thomas Michael Ross Executive Vice President of Global Sales -- -- 1961
Mr. Jack Horgan Vice President of Corporate Development -- -- --
Ms. Jill Mayer Senior Vice President of Human Resources -- -- --

MaxCyte, Inc.

9713 Key West Avenue
Suite 400
Rockville, MD 20850
United States
301 944 1700 https://www.maxcyte.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
143

Description

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Corporate Governance

MaxCyte, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024
MaxCyte, Inc. Earnings Call